Autologous Blood for Full-thickness Macular Hole

Not Applicable

Terminated

• Conditions: Ophthalmopathy

• Registration Number: NCT05494229
• Lead Sponsor: Omer Othman Abdullah

Brief Summary

Autologous blood for primary and recurrent holes

Detailed Description

Utilizing whole autologous blood for closing both primary and recurrent holes. Here, we apply a drop of the taken whole blood over the hole, and the access blood will be aspirated on the macula with a silicon-tipped active back-flash cannula, to abolish all the possibilities of the fibrinogenic behavior of the whole blood composition, which might cause traction and recurrent hole formation. Therefore, only the hole will be filled with blood. The blood will be taken under completely sterile and aseptic conditions.

The air infusion will be raised after the valve of one of the trocars will be removed, to allow the air current to dry the clot inside the hole rapidly. Then air gas exchange will be performed to allow the clot to remain away from intraocular fluids for one to two weeks and abolish the possibility of the clot being dissolved.

Study Timeline

• Study First Submitted: 2022-08-06
• Study First Submitted QC: 2022-08-08
• Study First Posted: 2022-08-09
• Study Start: 2022-09-01
• Status Verified: 2023-03
• Primary Completion: 2023-03-01
• Study Completion: 2023-03-01
• Last Update Submitted: 2023-03-23
• Last Update Posted: 2023-03-27

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 5

Inclusion Criteria

• Primary and recurrent holes

Exclusion Criteria

• Lamellar and pseudoholes

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Anatomical outcome	The fourth week post-operatively	OCT

Secondary Outcome Measures

Name	Time	Method
Functional outcome	The fourth week post-operatively.	Best corrected visual acuity

Trial Locations

Locations (1)

Omer Othman Abdullah; 🇮🇶 Erbil, Iraq